BIR Publications
Source : https://www.birpublications.org/doi/10.1259/bjr.20210270
Therapy and prognosis of several solid and hematologic malignancies, including non-small cell lung cancer (NSCLC), have been favourably impacted by the introduction of immune checkpoint inhibitors (ICIs). Their mechanism of action relies on the principle that some cancers can evade immune surveillance by expressing surface inhibitor molecules, known as "immune checkpoints".
Conclusions: We will explore the role of radiomics in the setting of ICI-treated patients.